ERBB2 and breast carcinoma: The propensity of HER2-positive breast cancer to metastasize to the brain may be related to the improved survival of patients with HER2-directed therapy, the limited CNS penetration of HER2-directed agents, and the neuro-tropism of HER2-positive breast cancer (57).